PROCEPT BioRobotics completes prostate cancer study enrollment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to PROCEPT BioRobotics completes prostate cancer study enrollment
(NASDAQ: PRCT) Delayed: 20.60 -0.46 (2.18%)
Previous Close $21.06    52 Week High $ 
Open $21.26    52 Week Low $ 
Day High $21.50    P/E N/A 
Day Low $19.92    EPS $ 
Volume 2,025,907